1.68
Curis Inc Aktie (CRIS) Neueste Nachrichten
Market reaction to Curis Inc.’s recent newsAsset Safety Selection Using Quantitative Analysis - Newser
Exit strategy if you’re trapped in Curis Inc.Next Day Momentum Stock Forecasting Report - Newser
What makes Curis Inc. stock price move sharplyGiant Leap Stock Alerts - thegnnews.com
Curis Inc. Receives Buy Rating Due to Promising Clinical Developments and Strong Financial Position. - AInvest
Curis Files Prospectus Supplement for Stock Offering - MSN
Curis Inc. Receives Buy Rating Amid Promising Clinical Developments and Strong Financial Position - TipRanks
Curis targets enrolling 30–40 additional patients for NDA and EMA submissions as emavusertib studies advance - MSN
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st
Curis, Inc. Analysts Trim Price Target After Q2 Report - AInvest
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Curis, Inc. Reports Q2 2025 Financial and Clinical Progress - The Globe and Mail
Curis 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Curis, Inc. shares rise 1.74% intraday as Swiss president meets business leaders in Washington ahead of tariff talks. - AInvest
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q2 2025 Earnings Call Transcript - Insider Monkey
Curis Provides Second Quarter 2025 Business Update - BioSpace
Curis: Q2 Earnings Snapshot - New Haven Register
Curis Inc. Earnings Call: Progress Amid Challenges - TipRanks
Curis Inc. Q2 Earnings Call Highlights: Progress Amid Challenges - AInvest
Curis (CRIS) Q2 Loss Narrows 66% - The Motley Fool
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy Rating - TipRanks
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises - Investing.com
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises By Investing.com - Investing.com South Africa
Curis Inc: A High-Conviction Biotech Play with Accelerating Catalysts in Hematology - AInvest
Curis, Inc. Q2 2025: Unraveling Contradictions in Enrollment Strategy, FDA Dynamics, and PCNSL Data Expectations - AInvest
Transcript : Curis, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis Inc (CRIS) Q2 2025 Earnings: EPS of -$0.68 Beats Estimate, Revenue Hits $2.7 Million - GuruFocus
Biotech firm Curis Q2 revenue rises to $2.7 mln - MarketScreener
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
How strong is Curis Inc. company’s balance sheetTrack top-performing stocks effortlessly - Jammu Links News
What are the technical indicators suggesting about Curis Inc.Exceptional gains - Jammu Links News
Curis Inc Q2 2025 Earnings Report Preview: Revenue Expected to Reach $2.64 Million, Earnings at -$1.36 per Share - AInvest
What catalysts could drive Curis Inc. stock higher in 2025Achieve breakthrough investment performance - Jammu Links News
How does Curis Inc. compare to its industry peersGet real-time updates on market trends - Jammu Links News
What drives Curis Inc. stock priceUnmatched market gains - Jammu Links News
What are Curis Inc. company’s key revenue driversInvest smarter with daily trading signals - Jammu Links News
What are analysts’ price targets for Curis Inc. in the next 12 monthsTurn volatility into profit opportunities - Jammu Links News
What is Curis Inc. company’s growth strategyBreakthrough financial growth - Jammu Links News
Is it the right time to buy Curis Inc. stockPhenomenal trading returns - Jammu Links News
Can machine learning forecast Curis Inc. recoverySmart Stock Forecast Using AI Algorithms - newser.com
Is Curis Inc. a growth stock or a value stockExtraordinary profit generation - Jammu Links News
What institutional investors are buying Curis Inc. stockMaximize your returns with expert insights - Jammu Links News
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):